Lupin Ltd

LUPIN

Company Profile

  • Business description

    Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.

  • Contact

    Off. Western Express Highway
    3rd floor, Kalpataru Inspire
    Santacruz (East)
    MumbaiMH400055
    IND

    T: +91 2266402323

    E: [email protected]

    https://www.lupin.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2027

    Employees

    24,006

Stocks News & Analysis

stocks

ASX tech share tracking below guidance

Moat Rating downgraded for overvalued shares.
stocks

After plunge ASX blue chip undervalued

This company earns a moat from our analysts.
stocks

Older cohorts the budget losers, not necessarily the ASX listed insurers

Proposed legislation removes health insurance rebates.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,829.5017.300.20%
CAC 407,981.765.73-0.07%
DAX 4024,400.6592.730.38%
Dow JONES (US)49,363.88322.24-0.65%
FTSE 10010,330.556.800.07%
HKSE25,797.85122.670.48%
NASDAQ25,870.71220.02-0.84%
Nikkei 22560,550.59265.36-0.44%
NZX 50 Index12,974.32211.401.66%
S&P 5007,353.6149.44-0.67%
S&P/ASX 2008,604.7023.100.27%
SSE Composite Index4,169.5438.010.92%

Market Movers